Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Development Officer | August 21, 2023 | August 23, 2023 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date August 21, 2023 · Filed August 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,962 |
Reported balance
After 2023-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-21 · Sale · Disposed 1,490 · Balance 26,962 F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022. F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on September 9, 2022.
F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Issuer's Employee Stock Purchase Plan on September 13, 2022 for 448 shares, and on March 13, 2023 for 1,183 shares.
Vistagen Therapeutics, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09 | Direct | 17,600 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600 F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,314 | $11.00 | $25,454.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 9 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 334 | $20.92 | $6,985.71 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 8 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.87 to $21.00, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 334 | $2.90 | $967.53 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,828 | $20.48 | $37,429.58 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.85 to $20.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,828 | $2.90 | $5,295.35 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 100 | $21.00 | $2,100.00 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 100 | $6.37 | $637.28 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 978 | $20.54 | $20,092.23 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.96 to $20.90, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 978 | $6.37 | $6,232.60 |
DisclosureSEC source: 0001209191-22-051002 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 20:41 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 988 | $18.63 | $18,406.44 |
DisclosureSEC source: 0001209191-22-049176 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 1,630 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · derivative · entry 21 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,917 Underlying: Class A Common Stock · 1,630 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 600 | $19.65 | $11,787.42 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 17 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F10 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $19.91, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 600 | $11.00 | $6,600.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 16 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,030 | $18.42 | $18,976.82 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 15 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F9 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.20 to $18.75, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,030 | $11.00 | $11,330.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 14 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Options (right to buy) · Derivative | 3,670 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · derivative · entry 20 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,547 Underlying: Class A Common Stock · 3,670 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 13, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 2,161 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · derivative · entry 19 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,598 Underlying: Class A Common Stock · 2,161 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 1,078 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · derivative · entry 18 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,951 Underlying: Class A Common Stock · 1,078 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 904 | $19.81 | $17,904.17 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 13 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F8 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.56 to $20.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 904 | $11.00 | $9,944.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 12 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,766 | $18.61 | $51,479.13 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 11 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F7 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.24 to $19.23, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 2,766 | $11.00 | $30,426.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 10 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 1,451 | $19.87 | $28,829.19 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 9 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F6 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.70 to $20.02, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 1,451 | $2.90 | $4,203.26 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 8 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 710 | $18.93 | $13,441.15 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F5 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.50 to $19.30, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 710 | $2.90 | $2,056.73 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 700 | $19.76 | $13,832.49 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F4 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.56 to $20.00, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 700 | $6.37 | $4,460.96 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 378 | $18.89 | $7,138.68 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $18.49 to $19.24, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 378 | $6.37 | $2,408.92 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047172 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,785 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under Issuer's 2021 Equity Incentive Plan. One-third of the RSUs vest on August 20, 2023, rounded to the nearest whole share, and the remaining RSUs vest on August 20, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 988 | $16.81 | $16,608.28 |
DisclosureSEC source: 0001209191-22-044412 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,285 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 6,054 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · derivative · entry 10 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,759 Underlying: Class A Common Stock · 6,054 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 5,390 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · derivative · entry 9 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,029 Underlying: Class A Common Stock · 5,390 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 8 | $16.55 | $132.36 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 8 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.53 to $16.56, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 8 | $2.90 | $23.17 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,046 | $16.01 | $96,810.37 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.46 to $16.45, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,046 | $2.90 | $17,514.05 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6 | $16.55 | $99.30 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6 | $6.37 | $38.24 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 5,384 | $16.02 | $86,229.07 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.46 to $16.45, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 5,384 | $6.37 | $34,311.16 |
DisclosureSEC source: 0001209191-22-042675 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:41 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 6,354 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-042255 · doc4.xml · derivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,813 Underlying: Class A Common Stock · 6,354 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:41 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,750 | $15.17 | $41,729.60 |
DisclosureSEC source: 0001209191-22-042255 · doc4.xml · nonDerivative · entry 3 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.57, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:41 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 6,354 | $15.13 | $96,134.11 |
DisclosureSEC source: 0001209191-22-042255 · doc4.xml · nonDerivative · entry 2 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.55, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 20:41 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 6,354 | $2.90 | $18,406.27 |
DisclosureSEC source: 0001209191-22-042255 · doc4.xml · nonDerivative · entry 1 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 3,514 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · derivative · entry 7 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,167 Underlying: Class A Common Stock · 3,514 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 3,487 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · derivative · entry 6 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,419 Underlying: Class A Common Stock · 3,487 shares Expires 2030-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,665 | $15.03 | $40,054.15 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · nonDerivative · entry 5 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,023 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:04 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,514 | $15.08 | $52,978.47 |
DisclosureSEC source: 0001209191-22-041771 · doc4.xml · nonDerivative · entry 4 Curley Joanne · CIK 0001857670 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.